Contact Information: At RegeneRx: At the Financial |
RegeneRx Enters Into Research Agreement with U. of Texas Southwestern Medical Center RegeneRx Enters Into Research Agreement with U. of Texas Southwestern Medical Center UT Southwestern to Study Tß4 in Cardiac Field August 30, 2001 — Bethesda, Md RegeneRx Biopharmaceuticals, Inc. (OTCBB: RGRX), announced today that it has entered into a Materials Transfer Agreement with the University of Texas Southwestern Medical Center at Dallas to explore the role of Thymosin Beta 4 (Tß4) in the cardiac field. Under the Agreement, the company will provide quantities of Tß4, as well as certain know-how and data, to UT Southwestern for certain research and development. In return, the Company may use any invention or discovery for internal research purposes and retains an option to negotiate an exclusive, worldwide, royalty-bearing license for commercialization. Tß4 is a synthetic version of a natural peptide found throughout the body and in highest concentrations in blood platelets. Studies at the National Institutes of Health have shown that Tß4 stimulates angiogenesis (formation of new blood vessels), reduces inflammation, and regulates actin, a molecule necessary for the movement of cells throughout the body. Recently published papers in a number of prestigious scientific journals have documented that Tß4 is effective in accelerating the healing of dermal and ocular wounds in various animal models. RegeneRx is presently developing Tß4 for the treatment of chronic wounds, a $7 billion annual market in the U.S. The company is completing pre-clinical work related to Tß4 prior to filing an IND scheduled for later this year or early 2002 and hopes to begin clinical trials in early 2002. The information in this press release includes certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements concern the Company's current expectations regarding future events, including the ongoing and prospective development and commercialization of Tß4 and possible future benefits to the Company, its shareholders, and patients. Due to the nature of product development and the regulatory approval process, the forward-looking statements contained in this press release are subject to risks and uncertainties, including those reflected in the Company's filings with the Securities and Exchange Commission, particularly its most recent Annual Report on Form 10-KSB. The Company assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the Company. |
